Forbes reports that pharmaceutical giant GlaxoSmithKline’s stock prices haven’t dropped at all in the wake of a historic $3 billion settlement with the U.S. Justice Department over illegally marketing drugs.
“Paying the Department of Justice settlements are apparently just a cost of the drug business,” Forbes states.
According to Forbes, GlaxoSmithKline sold medication to treat depression in kids under 18, despite a lack of pediatric approval. It also promoted depression drug Wellbutrin ...
continue reading...
In a recent article in the scientific journal Scientifica, two mental health professionals call for a redefinition of the term “antidepressant.”
An opinion piece in The Atlantic about the $3 billion settlement against GlaxoSmithKline makes the point that even a relatively large financial penalty is unlikely to stop a company that still makes a profit from illegal activities. The solution, The Atlantic says, is to change a system that essentially allows companies to monitor themselves.
Dr. Drew Pinsky – well-known as TV and radio host “Dr. Drew” – is dealing with criticism after court records revealed that he took $275,000 from GlaxoSmithKline for “services for Wellbutrin.”
In a piece for the Wall Street Journal, writer Katherine Sharpe argues that antidepressants are overprescribed in the United States, and discusses the challenges that face a growing segment of population – young people who have no conception of who they are when they aren’t on antidepressants.
